WuXi Biologics (Cayman) (MEX:2269) COGS-to-Revenue : 0.57 (As of Dec. 2024)

View and export this data going back to 2020. Start your Free Trial

What is WuXi Biologics (Cayman) COGS-to-Revenue?

WuXi Biologics (Cayman)'s Cost of Goods Sold for the six months ended in Dec. 2024 was MXN16,615 Mil. Its Revenue for the six months ended in Dec. 2024 was MXN28,935 Mil.

WuXi Biologics (Cayman)'s COGS to Revenue for the six months ended in Dec. 2024 was 0.57.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. WuXi Biologics (Cayman)'s Gross Margin % for the six months ended in Dec. 2024 was 42.58%.

WuXi Biologics (Cayman) COGS-to-Revenue Historical Data

The historical data trend for WuXi Biologics (Cayman)'s COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

WuXi Biologics (Cayman) COGS-to-Revenue Chart

WuXi Biologics (Cayman) Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

COGS-to-Revenue

Get a 7-Day Free Trial

0.55

0.53

0.56

0.60

0.59

WuXi Biologics (Cayman) Semi-Annual Data
	Dec14	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
COGS-to-Revenue	Get a 7-Day Free Trial															0.59	0.58	0.62	0.61	0.57

WuXi Biologics (Cayman) COGS-to-Revenue Calculation

WuXi Biologics (Cayman)'s COGS to Revenue for the fiscal year that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	31580.03	/	53495.946
	=	0.59

WuXi Biologics (Cayman)'s COGS to Revenue for the quarter that ended in Dec. 2024 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	16615.032	/	28934.951
	=	0.57

WuXi Biologics (Cayman) (MEX:2269) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

WuXi Biologics (Cayman)'s Gross Margin % for the six months ended in Dec. 2024 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	16615.032 / 28934.951
	=	42.58 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

WuXi Biologics (Cayman) COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of WuXi Biologics (Cayman)'s COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

WuXi Biologics (Cayman) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » WuXi Biologics (Cayman) Inc (MEX:2269) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

WXIBF:USA WXXWY:USA 02269:Hong Kong 1FW2:Germany

Address

No. 108, Meiliang Road, Mashan Binhu District, Wuxi, CHN, 214092

Website

https://www.wuxibiologics.com

WuXi Biologics is one of the largest global biologic global contract development and manufacturing organizations. WuXi Biologics, incorporated in 2014 following the reorganization of WuXi PharmaTech, later known as WuXi AppTec, now has global revenue of CNY 18.7 billion. North America represented 57.3% of total revenue in 2024. The firm has a "follow and win the molecule" strategy by providing end-to-end services, from drug discovery to commercial manufacturing. It also adopts a global dual sourcing strategy by providing drug products and drug substance manufacturing.

WuXi Biologics (Cayman) Headlines

No Headlines